Physician profile
Marta Khris
NPI 1093802928
$3,057.76
in general payments reported to CMS, 2019-2025
16 companies · $727 in 2025
The $727 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $303 · 2021: $338 · 2022: $259 · 2023: $604 · 2024: $508 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.11 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $457.07 | 2022-2025 | |
| Exact Sciences Corporation | $440.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $438.74 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $353.94 | 2019-2022 | |
| Pfizer INC. | $283.29 | 2020-2023 | |
| Astellas Pharma US INC | $253.21 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $187.47 | 2019-2023 | Arexvy, Shingrix |
| Lilly USA, LLC | $183.99 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.81 | 2019-2024 | Jardiance |
| Amgen INC. | $118.98 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $47.90 | 2019-2020 | |
| Phadia US INC. | $42.09 | 2023-2024 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $28.72 | 2023 | Jynarque |
| Medtronic Vascular, INC. | $23.54 | 2020 | |
| Merck Sharp & Dohme LLC | $17.07 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linus Health, INC. | $16.15 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Khris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.